Loading
IBI3032 tablets / Part A: Healthy Part B: Overweight Or Obesity · Phase 1 Trial
ClinicalTrials.gov · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 clinical trial registration for IBI3032, a drug under development for obesity and overweight conditions. The study is complete and recruited 80 participants, but no efficacy, safety, or pharmacokinetic results are posted in this registry record.
Phase 1, Interventional, Randomized, Sequential, Double masking, Treatment purpose. Part A: Healthy Part B: Overweight or Obesity; age from 18 Years; to 65 Years; accepts healthy volunteers. Intervention: Single dose of IBI3032 administered orally.; Multiple doses of IBI3032 administered orally.. Compared with: Single dose of placebo administered orally. — Placebo Comparator; Multiple doses of placebo administered orally. — Placebo Comparator. n = 80. 1 site: China.
This is a Phase 1 clinical trial registration for IBI3032, a drug under development for obesity and overweight conditions. The study is complete and recruited 80 participants, but no efficacy, safety, or pharmacokinetic results are posted in this registry record.
This is a registry record only; no results, adverse events, or efficacy data are reported. Primary outcome measures are safety and tolerability, not efficacy endpoints.
The source did not state who this applies to in practice.
Phase 1 registry record with no results posted; describes planned safety and tolerability assessment in healthy volunteers and obese participants with single and multiple ascending doses.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07160400). This is a study registration, not published results. Lead sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center). Recruitment status: COMPLETED. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 80 participants (ACTUAL). Conditions: Part A: Healthy Part B: Overweight or Obesity. Interventions: DRUG: Placebo; DRUG: IBI3032 tablets. Primary outcome measures: Number of Participants with adverse events (AEs) , Part A: Baseline up to Day 15; Number of Participants with adverse events (AEs) , Part B: Baseline up to Day 43; Number of Participants with One Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug , Part A: Baseline up to Day 15; Number of Participants with One Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug , Part B: Baseline up to Day 43; Number of Participants with More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug , Part A: Baseline up to Day 15; Number of Participants with More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug , Part B: Baseline up to Day 43. Brief summary: This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose of IBI3032 in healthy participants and multiple ascending doses of IBI3032 in participants with overweight or obesity. It consists of 2 parts: Part A is a single ascending dose (SAD) study in healthy participants, and Part B is a multiple ascending dose (MAD) study in participants with overweight or obesity during the 4-week treatment period.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.